Results 91 to 100 of about 29,467 (290)
Metabolic syndrome does not affect sustained virologic response of direct-acting antivirals while hepatitis C clearance improves hemoglobin A1c. [PDF]
AimTo determine whether successful treatment with directacting antivirals (DAA) is associated with improvements in hemoglobin A1c (HbA1c) and if type 2 diabetes mellitus (T2DM) or metabolic syndrome affects sustained virologic response (SVR).MethodsWe ...
Aby, Elizabeth S +6 more
core
HCV treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. [PDF]
UNLABELLED: Substantial reductions in hepatitis C virus (HCV) prevalence among people who inject drugs (PWID) cannot be achieved by harm reduction interventions such as needle exchange and opiate substitution therapy (OST) alone. Current HCV treatment is
Aitken +56 more
core +5 more sources
Antimicrobial peptide (AMP)‐loaded nanocarriers provide a multifunctional strategy to combat drug‐resistant Mycobacterium tuberculosis. By enhancing intracellular delivery, bypassing efflux pumps, and disrupting bacterial membranes, this platform restores phagolysosome fusion and macrophage function.
Christian S. Carnero Canales +11 more
wiley +1 more source
Hepatitis C Treatment: A Review and Update
Hepatitis C virus infection (HCV) infects approximately 185 million individuals worldwide. It is a leading cause of chronic liver disease and the primary reason for liver transplantation.
Jelena Jakab +4 more
doaj +1 more source
Dynamic modelling of hepatitis C virus transmission among people who inject drugs: a methodological review [PDF]
Equipment sharing among people who inject drugs (PWID) is a key risk factor in infection by hepatitis C virus (HCV). Both the effectiveness and cost-effectiveness of interventions aimed at reducing HCV transmission in this population (such as opioid ...
Cousien, Anthony +5 more
core +5 more sources
Cerebral organoids are transforming brain research, yet the field remains fragmented. This comprehensive systematic review maps 738 studies published between 2014 and 2024 to uncover trends, gaps, and opportunities across neuroscience. Introducing OrganoidMap—an interactive, open‐access platform to explore and compare models—this work enables ...
Anna Wolfram +10 more
wiley +1 more source
Profile of alisporivir and its potential in the treatment of hepatitis C
Philippe A Gallay,1 Kai Lin21Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA, 2Permeon Biologics Inc, One Kendall Square, Cambridge, MA, USAAbstract: Two classes of hepatitis C antiviral agents currently exist,
Gallay PA, Lin K
doaj
Aims: To estimate the number of patients that have access to treatment of hepatitis C with direct-acting antivirals in Argentina and evaluate the factors associated with the lack of access.
S. Marciano +22 more
doaj +1 more source
Curing Hepatitis C in Liver Transplant Recipients Is Associated with Changes in Immunosuppressant Use. [PDF]
Background and aimsAll-oral interferon-free antivirals are highly effective in treating recurrent hepatitis C (HCV) infection in liver transplant (LT) recipients.
Bau, Sherona +12 more
core +2 more sources
By fusing ACE2‐overexpressing membrane‐integrated liposome (MIL) with copper nanoparticles, the biomimetic Cu@MIL nanostructures were created that directly hijack the SARS‐CoV‐2 entry pathway. These particles combine potent virus‐targeting precision with intrinsic antiviral activity, achieving rapid neutralization and disinfection.
Pooja Aich +8 more
wiley +1 more source

